Kumari Kamlesh, Gombar Satinder, Kapoor Dheeraj, Sandhu Harpreet Singh
Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Anaesthesia and Intensive Care, Government Medical College and Hospital, Chandigarh, India.
Acta Anaesthesiol Taiwan. 2015 Dec;53(4):123-30. doi: 10.1016/j.aat.2015.09.003. Epub 2015 Oct 26.
Dexmedetomidine, an α2 agonist, has been evaluated for its hypnotic, analgesic, and anxiolytic properties in the intraoperative period and critical care setting. However, data on the effect of dexmedetomidine on attenuation of pressor response to direct laryngoscopy and tracheal intubation are limited. We studied the effect of a single preinduction intravenous dose of dexmedetomidine of 0.5 μg/kg on hemodynamic responses to tracheal intubation, and dose requirements of anesthetics for induction and their adverse effects.
Eighty adult patients scheduled for elective surgery under general anesthesia requiring tracheal intubation were included. Patients were randomized into two groups: dexmedetomidine and placebo (n = 40 each). The study drug was administered intravenously over a period of 10 minutes prior to induction. Direct laryngoscopy and endotracheal intubation were performed. Hemodynamic parameters, the total dose of propofol, and adverse effects were recorded during induction and postintubation periods for 15 minutes.
The maximum percentage increase in the heart rate after intubation was 19.6% less in the dexmedetomidine group than that in the placebo group (12.96% vs. 32.57%). The maximum percentage increases in systolic blood pressure, diastolic blood pressure, and mean blood pressure after intubation were significantly lower in the dexmedetomidine group than in the placebo group (12.38% vs. 45.63%, 19.36% vs. 60.36%, and 15.34% vs. 50.33%, respectively). There was a significant reduction of the mean total dose of propofol required for induction, 1.04 mg/kg in the dexmedetomidine group versus 2.01 mg/kg in the placebo group (p < 0.001). No serious side effects or adverse reactions were observed in either group.
Administration of a single preinduction intravenous dose of dexmedetomidine of 0.5 μg/kg resulted in significant attenuation of the rise in the heart rate, systolic blood pressure, diastolic blood pressure, and mean blood pressure, until 5 minutes postintubation. It significantly reduced the dose requirements of propofol for induction and caused minimal side effects.
右美托咪定是一种α2激动剂,已在术中和重症监护环境中对其催眠、镇痛和抗焦虑特性进行了评估。然而,关于右美托咪定对直接喉镜检查和气管插管升压反应减弱作用的数据有限。我们研究了诱导前静脉注射单次剂量0.5μg/kg右美托咪定对气管插管血流动力学反应、诱导麻醉药剂量需求及其不良反应的影响。
纳入80例计划在全身麻醉下行择期手术且需要气管插管的成年患者。患者随机分为两组:右美托咪定组和安慰剂组(每组n = 40)。在诱导前10分钟内静脉注射研究药物。进行直接喉镜检查和气管插管。记录诱导期和插管后15分钟内的血流动力学参数、丙泊酚总剂量及不良反应。
插管后心率最大百分比增幅右美托咪定组比安慰剂组低19.6%(12.96%对32.57%)。插管后收缩压、舒张压和平均血压的最大百分比增幅右美托咪定组显著低于安慰剂组(分别为12.38%对45.63%、19.36%对60.36%、15.34%对50.33%)。诱导所需丙泊酚平均总剂量显著降低,右美托咪定组为1.04mg/kg,安慰剂组为2.01mg/kg(p < 0.001)。两组均未观察到严重副作用或不良反应。
诱导前静脉注射单次剂量0.5μg/kg右美托咪定可显著减弱插管后直至插管后5分钟心率、收缩压、舒张压和平均血压的升高。它显著降低了诱导所需丙泊酚剂量且副作用极小。